Tafamidis
Vyndamax, Vyndaqel (tafamidis) is a small molecule pharmaceutical. Tafamidis was first approved as Vyndamax on 2011-11-16. It has been approved in Europe to treat amyloidosis. It is known to target transthyretin. Vyndaqel's patents are valid until 2035-08-31 (FDA).
| Trade Name | Vyndaqel |
|---|---|
| Common Name | Tafamidis |
| Indication | amyloidosis |
| Drug Class | Antimyloidotics |
